FOLH1 and neoplasm: While [18F]AlF-NOTA(5)-DUPA-Pep is yet to be preclinically evaluated, [18F]AlF-PSMA-BCH entered a small clinical trial of 11 newly diagnosed PCa patients; the radioconjugate was well tolerated and visualised tumour lesions at 1 and 2 h p.i. (Liu et al. 2019).